Log In
BCIQ
Print this Print this
 

PRS-080

  Manage Alerts
Collapse Summary General Information
Company Pieris Pharmaceuticals Inc.
DescriptionAnticalin hepcidin antagonist
Molecular Target Hepcidin
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPhase I
Standard IndicationAnemia
Indication DetailsTreat anemia
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/18/2014

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today